Business context and reporting period
This is Pieris Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2017—not a filing for Palvella Therapeutics, Inc., as indicated in the request metadata. Pieris is a clinical-stage biotechnology company developing Anticalin protein therapeutics and relies primarily on collaboration and licensing revenue; it has no product sales to date.
Financial performance and position
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Revenue | $3.93 million | $0.79 million | $7.12 million | $3.10 million |
| Research and development | $6.26 million | $4.62 million | $17.01 million | $12.78 million |
| General and administrative | $2.85 million | $2.34 million | $11.19 million | $6.68 million |
| Operating loss | $(5.18) million | $(6.18) million | $(21.08) million | $(16.35) million |
| Net loss | $(7.06) million | $(6.20) million | $(25.14) million | $(16.24) million |
| Basic and diluted loss per share | $(0.16) | $(0.14) | $(0.58) | $(0.39) |
At September 30, 2017, cash was $89.9 million, up from $29.4 million at December 31, 2016; total assets were $98.9 million. Total liabilities were $94.3 million, including $86.6 million of deferred revenue. The balance sheet reports no borrowings or other debt. Stockholders’ equity was $4.6 million, compared with $25.2 million at year-end 2016.
For the first nine months, operating cash flow was positive $54.4 million, versus cash used of $7.7 million in 2016. The 2017 inflow chiefly reflected $78.0 million in increased deferred revenue and collaboration receipts, rather than operating profitability. Investing cash outflow was $1.1 million and financing cash inflow was $3.5 million. The filing gives no gross-margin measure; the company remains loss-making.
Material changes versus prior comparable periods
- Revenue increased 400% in Q3 and 129% for the first nine months, primarily from recognition under the new AstraZeneca and Servier collaborations. Collaboration revenue for the nine-month period rose to $6.17 million from $2.03 million.
- Operating expenses increased: nine-month R&D rose 33% to $17.0 million, with higher PRS-060, PRS-080 and non-core program costs; G&A rose 68% to $11.2 million, including $2.6 million of transaction fees related to the AstraZeneca, Servier and ASKA agreements.
- Nine-month net loss widened to $25.1 million from $16.2 million. Non-operating expense was $3.1 million, compared with $0.1 million of income in 2016, mainly due to euro-related foreign-currency transaction losses. The company also recorded $1.0 million of income tax expense, primarily related to Australian taxable income associated with AstraZeneca.
Outlook, management commentary and risks
- Management said September 30 cash was expected to fund the current operating plan for at least 12 months from the filing date. The company expects substantial losses and rising development costs for several years, and may require additional capital; financing availability and terms are uncertain.
- Management expected revenue in coming years mainly from collaboration upfront and milestone payments, reimbursed development costs and research funding. Product sales revenue was not expected for at least several years.
- Key programs included PRS-343, with first-patient dosing underway in a Phase I study; PRS-332 and other immuno-oncology programs; PRS-060, for which the company planned to begin dosing healthy volunteers in Q4 2017; and PRS-080, for which a Phase IIa anemia study had begun enrollment. The filing said the first PRS-060 subject’s dosing would trigger a $12.5 million AstraZeneca milestone.
- Collaboration terms create potential milestone and royalty opportunities, but these depend on development, regulatory, commercial and sales outcomes. AstraZeneca and Servier have termination rights, and Pieris may need to fund shared development costs if it elects co-development options.
- Principal risks include clinical and regulatory uncertainty, substantial future funding needs, dependence on partners and third parties, foreign-exchange exposure, and the possibility that financing may be unavailable on acceptable terms. The company reported no material change to the risk factors in its 2016 Form 10-K and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for Pieris Pharmaceuticals, not Palvella Therapeutics.
- Assess the sustainability of liquidity: operating cash flow benefited materially from collaboration payments and deferred revenue; reported cash is not evidence of operating profitability.
- Track recognition and performance obligations on the AstraZeneca, Servier, Roche and ASKA agreements, including the substantial deferred-revenue balance and conditions for future milestones.
- Monitor clinical progress, spending and milestone conditions for PRS-343, PRS-332, PRS-060 and PRS-080, as well as partner termination and co-development decisions.
- Review foreign-currency losses, dilution from equity awards and any future financing needs against management’s stated 12-month cash outlook.